2 unknown. 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Unknown 2 |
Follow Graft Versus Host Disease: new trials by email Literature Review of Graft Versus Host Disease trials Research Report on Graft Versus Host Disease
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Comparison of PT-Cy at a Dose of 25 mg/kg/Day and PT-Cy at a Dose of 50 mg/kg/Day in GVHD Prophylaxis Post-transplantation Cyclophosphamide at dose 25 mg/kg/day, Post-transplantation Cyclophosphamide at dose 50 mg/kg/day - Graft Versus Host Disease, Hematologic Malignancy | Phase 3 | Unknown | National Research Center for Hematology, Russia | 100 | 2022-01-01 | 2022-01-11 |
| Tacrolimus and Mycophenolate Mofetil as Post-Grafting Immunosuppression Tacrolimus and MMF. - Graft Versus Host Disease | Phase 3 | Unknown | Colorado Blood Cancer Institute | 50 | 2010-11-01 | 2014-07-01 |
Graft vs Host Disease (2) · Hematologic Neoplasms (1)
Immune System Diseases (2) · Hematologic Diseases (1) · Hemic and Lymphatic Diseases (1) · Neoplasms (1) · Neoplasms by Site (1)
Cyclophosphamide (1) · Mycophenolic Acid (1) · Tacrolimus (1) · trihexyltetradecylphosphonium chloride (1)
Colorado Blood Cancer Institute (1) · National Research Center for Hematology, Russia (1)
United States (1)
Elena Parovichnikova, MD, D.Sc (1) · Mark W Brunvand, MD (1)